文献速递垂体与肾上腺疾病

生长激素与泌乳素共分泌型及生长激素分泌型垂体腺瘤的差异:604例系列研究

Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

这项多中心回顾性研究纳入604例接受垂体手术的肢端肥大症患者,比较生长激素与泌乳素共分泌型垂体腺瘤(GH&PRL-PAs,n=130)与生长激素分泌型垂体腺瘤(GH-PAs,n=474)的临床特征与手术结局。GH&PRL-PAs占21.5%,诊断年龄更早,大腺瘤更多(90.6% vs 77.4%),术前垂体功能减退更多(OR 2.8),术后永久性精氨酸加压素缺乏更多(7.3% vs 2.4%),但即刻和长期生化治愈率无显著差异。

要点

  • GH&PRL-PAs占肢端肥大症的21.5%,诊断年龄较GH-PAs更早。
  • GH&PRL-PAs大腺瘤比例更高(90.6% vs 77.4%),侵袭性有增高趋势(33.6% vs 24.7%,P=.057)。
  • 两组术后生化治愈率无显著差异,但GH&PRL-PAs永久性AVP-D发生率更高(7.3% vs 2.4%)。

核心结论

  • GH&PRL-PAs约占肢端肥大症病例的20%,较GH-PAs更大、更具侵袭性、更常导致垂体功能减退,且诊断年龄更早。
  • 两组生化治愈率相似,但GH&PRL-PAs患者术后更易发生永久性精氨酸加压素缺乏(AVP-D)。

研究设计与样本

  • 多中心回顾性研究,纳入604例接受垂体手术的肢端肥大症患者。
  • 按诊断时血清PRL水平及PRL免疫组化分为GH&PRL-PAs组(n=130)和GH-PAs组(n=474)。

主要发现

  • GH&PRL-PAs占21.5%(n=130),诊断平均年龄低于GH-PAs(P<.001)。
  • GH&PRL-PAs大腺瘤比例90.6% vs GH-PAs 77.4%(P=.001),侵袭性33.6% vs 24.7%(P=.057)。
  • GH&PRL-PAs术前垂体功能减退更多(OR 2.8;95%CI 1.83-4.38)。
  • 诊断时IGF-ULN水平GH&PRL-PAs中位数2.4(IQR 1.73-3.29)vs GH-PAs 2.7(IQR 1.91-3.67),P=.023。
  • 术后即刻生化治愈率41.1% vs 43.3%(P=.659),长期生化治愈率53.5% vs 53.1%(P=.936);永久性AVP-D发生率7.3% vs 2.4%(P=.011)。

关键数值与推荐

  • GH&PRL-PAs定义:PRL水平高于正常上限且GH和PRL免疫组化阳性,或PRL>100 ng/dL且PRL免疫组化不可用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Few data exist about the clinical course of acromegaly, surgical and medical outcomes in patients with GH- and prolactin cosecreting pituitary adenomas (GH&PRL-PAs). Nevertheless, some series described a more aggressive clinic-radiological behavior than in growth hormone-secreting pituitary adenomas (GH-PAs). OBJECTIVE: This work aims to evaluate differences in clinical presentation and in surgical outcomes between GH-PAs and GH&PRL-PAs. METHODS: A multicenter retrospective study was conducted of 604 patients with acromegaly who underwent pituitary surgery. Patients were classified into 2 groups according to serum PRL levels at diagnosis and immunohistochemistry (IHC) for PRL: a) GH&PRL-PAs when PRL levels were above the upper limit of normal (ULN) and IHC for GH and PRL was positive or PRL levels were greater than 100 ng/dL and PRL IHC was not available (n = 130) and b) GH-PA patients who did not meet the previously mentioned criteria (n = 474). RESULTS: GH&PRL-PAs represented 21.5% (n = 130) of patients with acromegaly. The mean age at diagnosis was lower in GH&PRL-PAs than in GH-PAs (P < .001). GH&PRL-PAs were more frequently macroadenomas (90.6% vs 77.4%; P = .001) and tended to be more invasive (33.6% vs 24.7%; P = .057) than GH-PAs. Furthermore, they had presurgical hypopituitarism more frequently (odds ratio 2.8; 95% CI, 1.83-4.38). Insulin-like growth factor ULN levels at diagnosis were lower in patients with GH&PRL-PAs (median 2.4 [interquartile range (IQR) 1.73-3.29] vs 2.7 [IQR 1.91-3.67]; P = .023). There were no differences in the immediate (41.1% vs 43.3%; P = .659) or long-term postsurgical acromegaly biochemical cure rate (53.5% vs 53.1%; P = .936) between groups. However, there was a higher incidence of permanent arginine-vasopressin deficiency (AVP-D) (7.3% vs 2.4%; P = .011) in GH&PRL-PA patients. CONCLUSION: GH&PRL-PAs are responsible for 20% of acromegaly cases. These tumors are more invasive, larger, and cause hypopituitarism more frequently than GH-PAs and are diagnosed at an earlier age. The biochemical cure rate is similar between both groups, but patients with GH&PRL-PAs tend to develop permanent postsurgical AVP-D more frequently.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Araujo-Castro M, Biagetti B, Menéndez Torre E, et al. Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases. J Clin Endocrinol Metab. 2024. PMID: 38436926. doi:10.1210/clinem/dgae126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。